Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.390
+0.260 (23.01%)
At close: Aug 29, 2025, 4:00 PM
1.030
-0.360 (-25.90%)
Pre-market: Sep 2, 2025, 4:05 AM EDT
Rein Therapeutics Employees
Rein Therapeutics had 11 employees as of December 31, 2024. The number of employees decreased by 4 or -26.67% compared to the previous year.
Employees
11
Change (1Y)
-4
Growth (1Y)
-26.67%
Revenue / Employee
n/a
Profits / Employee
-$5,377,364
Market Cap
32.39M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11 | -4 | -26.67% |
Dec 31, 2023 | 15 | 9 | 150.00% |
Dec 31, 2022 | 6 | -3 | -33.33% |
Dec 31, 2021 | 9 | 1 | 12.50% |
Dec 31, 2020 | 8 | -5 | -38.46% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RNTX News
- 13 days ago - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 18 days ago - Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 - GlobeNewsWire
- 2 months ago - Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - PRNewsWire
- 2 months ago - US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters
- 3 months ago - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire
- 3 months ago - Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference - PRNewsWire
- 3 months ago - Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 4 months ago - Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire